Literature DB >> 19036487

Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.

Robbert Meerwaldt1, Clark J Zeebregts, Gerjan Navis, Jan-Luuk Hillebrands, Joop D Lefrandt, Andries J Smit.   

Abstract

Cardiovascular and connective tissue disorders are very common in patients with end-stage renal disease (ESRD), and the accumulation of advanced glycation end products (AGEs) is significantly increased in these patients. Accumulation of AGEs is believed to have a role in tissue protein aging and the pathogenesis of such age-related diseases as diabetes and ESRD. AGEs accumulate in patients with ESRD as a result of nonenzymatic glycation, oxidative stress, and diminished clearance of AGE precursors. Some AGEs show characteristic brown pigmentation and fluorescence, form protein-protein cross-links, and may ligate with AGE-specific receptors, inducing oxidative stress and cytokine production. This review focuses on the clinical relevance of AGE accumulation in patients with ESRD treated by dialysis for the development of long-term complications. The formation and accumulation of AGEs in patients with ESRD are discussed, as well as the relationship between AGE accumulation and such major complications of ESRD as cardiovascular and connective tissue disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036487     DOI: 10.1053/j.ajkd.2008.08.031

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  22 in total

1.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

2.  The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma.

Authors:  Noriko Himori; Hiroshi Kunikata; Yukihiro Shiga; Kazuko Omodaka; Kazuichi Maruyama; Hidetoshi Takahashi; Toru Nakazawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-30       Impact factor: 3.117

3.  Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Noha A Osman; Mona M Salem; Amr Nassef; Usama A A Sharaf El Din
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

Review 4.  Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.

Authors:  Clifford J Holmes
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

5.  Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.

Authors:  Mihaela Oleniuc; Irina Secara; Mihai Onofriescu; Simona Hogas; Luminita Voroneanu; Dimitrie Siriopol; Adrian Covic
Journal:  Maedica (Buchar)       Date:  2011-10

6.  Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

Authors:  Yao-Chen Chuang; Ming-Shiou Wu; Yi-Kai Su; Kwang-Ming Fang
Journal:  Cardiovasc Diabetol       Date:  2012-06-13       Impact factor: 9.951

7.  Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.

Authors:  Irena Makulska; Maria Szczepańska; Dorota Drożdż; Dorota Polak-Jonkisz; Danuta Zwolińska
Journal:  Pediatr Nephrol       Date:  2012-09-15       Impact factor: 3.714

8.  Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus.

Authors:  Yonatan Serlin; Jaime Levy; Hadar Shalev
Journal:  Cardiovasc Psychiatry Neurol       Date:  2011-02-17

9.  Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study.

Authors:  Angélica Rangel-López; Maria Eugenia Paniagua-Medina; Marcia Urbán-Reyes; Martha Cortes-Arredondo; Cleto Alvarez-Aguilar; Joel López-Meza; Alejandra Ochoa-Zarzosa; Bengt Lindholm; Elvia García-López; José Ramón Paniagua
Journal:  Mutagenesis       Date:  2013-03       Impact factor: 3.000

10.  The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition).

Authors:  Aowen Zhuang; Felicia Y T Yap; Danielle J Borg; Domenica McCarthy; Amelia Fotheringham; Sherman Leung; Sally A Penfold; Karly C Sourris; Melinda T Coughlan; Benjamin L Schulz; Josephine M Forbes
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.